A new SEC filing for Thermo Fisher Scientific Inc. (TMO) was recorded as of 1 August 2026, prompting renewed examination of the company's financial and ownership profile [Brief - 2026-08-17]. No additional briefing disclosures beyond that filing date were available for the current reporting period [Brief - 2026-09-11]. The filing prompted this review in conjunction with material institutional position changes identified in recent 13F disclosures.
For the trailing twelve months ending 2026-06-27, TMO recorded revenue of $46.34 billion, representing year-over-year growth of 10.49%. Net income for the same period stood at $6.98 billion, producing a net margin of 15.07%. Gross margin was 24.45% and operating margin 17.58%. Earnings per share grew 9.35% year-over-year. The company held $4.06 billion in cash against total debt of $45.65 billion. The price-to-earnings ratio was recorded at 35.04 [SEC 10-Q - TMO - 2026-06-27].
Insider activity in September 2026 recorded 49 transactions with a net directional disposition, totalling a net sold value of approximately $15.27 million [SEC Form 4 - TMO - 2026-09]. On the institutional side, five notable managers opened new positions in TMO during the most recent reporting period: Citadel (Ken Griffin), D1 Capital (Dan Sundheim), Millennium (Izzy Englander), AQR Capital (Cliff Asness), and Bridgewater (Ray Dalio) each initiated new holdings [SEC 13F - Citadel - Q2 2026] [SEC 13F - D1Capital - Q2 2026] [SEC 13F - Millennium - Q2 2026] [SEC 13F - AQRCapital - Q2 2026] [SEC 13F - Bridgewater - Q2 2026].
The prevailing macro environment at the time of this report showed the 10-year US Treasury yield (DGS10) at 4.94% and the 2-year yield (DGS2) at 4.67%, reflecting a normal yield curve configuration [FRED DGS10] [FRED DGS2]. This rate environment represents the broader context within which TMO's debt load of $45.65 billion and its equity valuation metrics are reported.
This report was generated in response to material institutional position changes, with five distinct large-scale managers each recording new TMO positions in the same reporting period. Concurrent insider disposition activity of approximately $15.27 million across 49 transactions was also noted during the same window [SEC Form 4 - TMO - 2026-09].